Funding profile · Life science research software

Biodock

One announced round in five years, no Regulation D notice on file, and a reported total that is $1.7 million larger than anything the company has ever announced.

Data as of September 23, 2026. Company-reported figures are labeled.

Rounds at a glance

What the filings show

Reading the filings

1. The absence of a Form D is not proof of nothing.A $2.1 million priced round can be sold under Section 4(a)(2) of the Securities Act, which carries no Regulation D notice requirement. What the absence does mean is that no investor count, no offering size, no first sale date and no related person list exists in any public file for this company. Every capital figure here traces back to the company or its founder.
2. The announcement and the founder disagree by $100,000.The March 30, 2021 blog post says $2.1 million. In January 2026 the founder told Digital Business “We raised $2.2 million in that round.” Neither number is filed anywhere. On a round this size the discrepancy is 4.8 percent, which is the size of a late angel check or a rounding habit, not a material restatement.
3. $1.7 million has no announcement attached.Take the founder’s January 2026 total of $3.8 million and subtract the announced pre-seed of $2.1 million. The remainder is $1.7 million, roughly 45 percent of all capital, raised across five years with no press release, no Form D and no named investor. A grant, a bridge note, a safe extension or revenue reinvested are all consistent with the record. So is nothing at all beyond the founder’s arithmetic.
4. The grant the federal record does not carry.The founder says he and his co-founder received a National Science Foundation grant before settling on the idea. A search of the NSF awards database for the company name returns no awards, and NIH RePORTER returns none. If it exists it sits under a university or personal name, common for Stanford work, but it is not on the company’s name in any record we can read.
5. Two data vendors disagree about revenue by a factor of two to four.GetLatka carries an estimate of $1.2 million of annual revenue for 2024 and lists funding as $0. Extruct carries a range of $2 million to $5 million. Both are models, not disclosures, and one of them shows $0 raised for a company that announced $2.1 million from Andreessen Horowitz.
6. The headcount and the geography moved together.The founder put the team at around ten people in January 2026. Data vendors show eight. The open engineering roles on the Y Combinator listing are posted in Astana, Kazakhstan and remote across Central Asia, with bands from $18K to $50K. With one announced round and no visible follow-on, moving engineering to a lower cost base is what keeps a small team funded off revenue.

Commercial signals

What to watch

• A first Form D. It would be the first machine readable number this company has ever produced.
• Any breakdown of the $1.7 million between the announced round and the reported total.
• Confirmation of an enterprise account beyond Vaxxas from a release, a filing or a paper.
• Whether the citation rate, weighted to 2025 and 2026, converts into paid seats or stays academic goodwill.
• Whether the August 2026 rebuild and the paid academic tier show up as a pricing page rather than a sales call.

The Biodock story on Healthcare DiscoveryHealthcare Discovery

Related companies

• Apero Health: Shared investor: Andreessen Horowitz. An API driven practice management platform that folds scheduling, visit notes, insurance billing, patient payments and e-prescriptions into one system for medical
• dNovo: Shared investor: Soma Capital. A Stanford trained biologist's direct reprogramming system once grew human hair on the backs of lab mice
• Kopra Bio: Shared investor: Andreessen Horowitz. A UCSF spinout engineering a virus that turns brain tumor cells into local factories for an immune-stimulating protein
• Experiment: Shared investor: Andreessen Horowitz. A crowdfunding site where a graduate student can raise three thousand dollars in a month instead of waiting a year for a grant

Sources

1. Public recordSEC EDGAR full text search and company search for Biodock, zero resultsSEC · Sep 23, 2026
2. Public recordNSF awards database query for Biodock, zero awardsNSF · Sep 23, 2026
3. Public recordEurope PMC literature search for Biodock, 57 recordsEurope PMC · Sep 23, 2026
4. Public recordEvaluation of the self-administration potential of high-density microarray patches to human skin, disclosure statement naming VaxxasHuman Vaccines and Immunotherapeutics · Mar 22, 2023
5. IndependentKazakh scientist moves to the US and builds a biotech startup that’s already raised $3.8 millionDigital Business, Lizaveta Filonenka · Jan 16, 2026
6. IndependentBiodock revenue and team estimatesGetLatka · accessed Sep 23, 2026
7. IndependentBiodock funding and revenue profile, $2M to $5M estimateExtruct · accessed Sep 23, 2026
8. IndependentBiodock organization profileStartup Intros · accessed Sep 23, 2026
9. CompanyAnnouncing Biodock’s pre-seed roundBiodock blog, Michael Lee · Mar 30, 2021
10. CompanyThe new Biodock is live, including the new academic tierBiodock blog · Aug 24, 2026
11. CompanyBiodock company page and open roles in AstanaY Combinator · accessed Sep 23, 2026
12. CompanyBiodock security pagebiodock.ai · accessed Sep 23, 2026

Compiled from SEC, NSF, NIH, FDA and Europe PMC public records and published reports as of September 23, 2026. No Form D notice has been filed by or for this company, so every capital figure on this page originates with the company or its founder. Healthcare Venture Capital Fund holds no position in Biodock. This page is not an offer to sell or a recommendation to buy any security.